We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eton Pharmaceuticals Inc | NASDAQ:ETON | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.71 | 3.00 | 4.00 | 0 | 09:00:01 |
From May 2021 to May 2024
By Colin Kellaher
Eton Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration approved the company's Rezipres ephedrine hydrochloride injection for the treatment of clinically important hypotension occurring in the setting of anesthesia.
The Deer Park, Ill., drugmaker said Rezipres marks its second FDA-approved ready-to-use hospital injectable product.
Eton last month said the FDA had turned away its application for approval of a dehydrated alcohol injection for the treatment of methanol poisoning, saying it couldn't approve the application in its current form. Eton at the time said it believes it can address the agency's concerns in the coming months.
Trading in shares of Eton was halted Tuesday morning.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 15, 2021 11:05 ET (15:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eton Pharmaceuticals Chart |
1 Month Eton Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
